J. Peréz-García, A. Llombart-Cussac, E. Holgado, G. Curigliano, E. Miranda, J. L. Alonso-Romero, B. Bermejo, L. Calvo, V. Carañana, Susana de la Cruz Sánchez, M. Cortés, R. M. Vázquez, A. Prat, M. R. Borrego, M. Sampayo, M. Seguí, J. Soberino, A. Malfettone, P. Schmid, J. Cortés
{"title":"摘要P3-09-03: pembrolizumab和eribulin在先前接受过蒽环类药物和紫杉烷治疗的hr阳性/ her2阴性转移性乳腺癌患者中的II期研究(KELLY研究)","authors":"J. Peréz-García, A. Llombart-Cussac, E. Holgado, G. Curigliano, E. Miranda, J. L. Alonso-Romero, B. Bermejo, L. Calvo, V. Carañana, Susana de la Cruz Sánchez, M. Cortés, R. M. Vázquez, A. Prat, M. R. Borrego, M. Sampayo, M. Seguí, J. Soberino, A. Malfettone, P. Schmid, J. Cortés","doi":"10.1158/1538-7445.sabcs19-p3-09-03","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)\",\"authors\":\"J. Peréz-García, A. Llombart-Cussac, E. Holgado, G. Curigliano, E. Miranda, J. L. Alonso-Romero, B. Bermejo, L. Calvo, V. Carañana, Susana de la Cruz Sánchez, M. Cortés, R. M. Vázquez, A. Prat, M. R. Borrego, M. Sampayo, M. Seguí, J. Soberino, A. Malfettone, P. Schmid, J. Cortés\",\"doi\":\"10.1158/1538-7445.sabcs19-p3-09-03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20307,\"journal\":{\"name\":\"Poster Session Abstracts\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Session Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Session Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)